Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests
Mojgan Masoodi, Amalia Gastaldelli, Tuulia Hyötyläinen, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 12, pp. 835-856
Closed Access | Times Cited: 314

Showing 1-25 of 314 citing articles:

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
Kenneth Cusi, Scott Isaacs, Diana Barb, et al.
Endocrine Practice (2022) Vol. 28, Iss. 5, pp. 528-562
Open Access | Times Cited: 655
The multifaceted role of ferroptosis in liver disease
Junyi Chen, Xiaopeng Li, Chaodong Ge, et al.
Cell Death and Differentiation (2022) Vol. 29, Iss. 3, pp. 467-480
Open Access | Times Cited: 421
Small molecule metabolites: discovery of biomarkers and therapeutic targets
Shi Qiu, Ying Cai, Hong Yao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 365
Lipid alterations in chronic liver disease and liver cancer
Bichitra Paul, Monika Lewińska, Jesper B. Andersen
JHEP Reports (2022) Vol. 4, Iss. 6, pp. 100479-100479
Open Access | Times Cited: 200
The associations between modifiable risk factors and nonalcoholic fatty liver disease: A comprehensive Mendelian randomization study
Jiarong Xie, Hangkai Huang, Zhening Liu, et al.
Hepatology (2022) Vol. 77, Iss. 3, pp. 949-964
Open Access | Times Cited: 163
Impact of non-invasive biomarkers on hepatology practice: Past, present and future
Quentin M. Anstee, Laurent Castéra, Rohit Loomba
Journal of Hepatology (2022) Vol. 76, Iss. 6, pp. 1362-1378
Open Access | Times Cited: 149
Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis
Delilah Hendriks, Jos F. Brouwers, Karien M. Hamer, et al.
Nature Biotechnology (2023) Vol. 41, Iss. 11, pp. 1567-1581
Open Access | Times Cited: 107
Gut symbionts alleviate MASH through a secondary bile acid biosynthetic pathway
Qixing Nie, Xi Luo, Kai Wang, et al.
Cell (2024) Vol. 187, Iss. 11, pp. 2717-2734.e33
Open Access | Times Cited: 77
Metabolic syndrome
Ian J. Neeland, Soo Lim, André Tchernof, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 50
NASH drug treatment development: challenges and lessons
Herbert Tilg, Christopher D. Byrne, Giovanni Targher
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 10, pp. 943-954
Open Access | Times Cited: 49
Systemic immune-inflammatory biomarkers (SII, NLR, PLR and LMR) linked to non-alcoholic fatty liver disease risk
Ke Liu, Shiyun Tang, Chenhao Liu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 33
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 454-499
Open Access | Times Cited: 31
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions
Lung‐Yi Mak, Ken Liu, Sakkarin Chirapongsathorn, et al.
Nature Reviews Gastroenterology & Hepatology (2024) Vol. 21, Iss. 12, pp. 834-851
Closed Access | Times Cited: 29
Development of Polymethine Dyes for NIR‐II Fluorescence Imaging and Therapy
Xin Chen, Jieyan Li, Shubham Roy, et al.
Advanced Healthcare Materials (2024) Vol. 13, Iss. 16
Closed Access | Times Cited: 23
Gut microbiota and metabolic biomarkers in metabolic dysfunction–associated steatotic liver disease
Qichen Long, Fengming Luo, Binghui Li, et al.
Hepatology Communications (2024) Vol. 8, Iss. 3
Open Access | Times Cited: 22
Exposure to environmental toxicants is associated with gut microbiome dysbiosis, insulin resistance and obesity
Partho Sen, Yong Fan, Jennifer J. Schlezinger, et al.
Environment International (2024) Vol. 186, pp. 108569-108569
Open Access | Times Cited: 20
Opportunities and barriers in omics-based biomarker discovery for steatotic liver diseases
Maja Thiele, Ida Falk Villesen, Lili Niu, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 2, pp. 345-359
Open Access | Times Cited: 16
Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024)
Jian‐Gao Fan, Xiaoyuan Xu, Rui-Xu Yang, et al.
Journal of Clinical and Translational Hepatology (2024) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 16
Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease
Aidan McGlinchey, Olivier Govaere, Dawei Geng, et al.
JHEP Reports (2022) Vol. 4, Iss. 5, pp. 100477-100477
Open Access | Times Cited: 66
NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy
Matthias Pinter, David J. Pinato, Pierluigi Ramadori, et al.
Clinical Cancer Research (2022) Vol. 29, Iss. 3, pp. 513-520
Open Access | Times Cited: 61
Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals
Chiara Saponaro, Silvia Sabatini, Melania Gaggini, et al.
Liver International (2022) Vol. 42, Iss. 11, pp. 2418-2427
Open Access | Times Cited: 60
Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches
Eirini Martinou, Marinos Pericleous, Irena Stefanova, et al.
Diagnostics (2022) Vol. 12, Iss. 2, pp. 407-407
Open Access | Times Cited: 49
Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles
Ibon Martínez‐Arranz, Chiara Bruzzone, Mazen Noureddin, et al.
Hepatology (2022) Vol. 76, Iss. 4, pp. 1121-1134
Open Access | Times Cited: 49
Nanomaterials‐assisted metabolic analysis toward in vitro diagnostics
Jing Yang, Lin Huang, Kun Qian
Exploration (2022) Vol. 2, Iss. 3
Open Access | Times Cited: 44
Noni (Morinda citrifolia L.) fruit phenolic extract supplementation ameliorates NAFLD by modulating insulin resistance, oxidative stress, inflammation, liver metabolism and gut microbiota
Ruimin Wang, Lu Wang, Haibo Wu, et al.
Food Research International (2022) Vol. 160, pp. 111732-111732
Closed Access | Times Cited: 41
Page 1 - Next Page

Scroll to top